Wave Life Sciences (WVE) Projected to Post Quarterly Earnings on Tuesday

Wave Life Sciences (NASDAQ:WVE) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $25.60 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Wave Life Sciences Stock Performance

Shares of Wave Life Sciences stock opened at $10.57 on Monday. The stock has a market capitalization of $1.61 billion, a P/E ratio of -9.52 and a beta of -1.09. Wave Life Sciences has a 52-week low of $4.25 and a 52-week high of $16.74. The stock’s 50-day simple moving average is $11.74 and its 200 day simple moving average is $11.08.

Analyst Ratings Changes

A number of brokerages recently commented on WVE. Mizuho upped their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 target price on the stock. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Finally, Truist Financial raised their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.